Prolonged Hypocalcemic Effect by Pulmonary Delivery of Calcitonin Loaded Poly(Methyl Vinyl Ether Maleic Acid) Bioadhesive Nanoparticles

Table 7

Pharmacodynamics of sCT after iv and pulmonary administration to rats.

Formulation	Dose (µg kg^−1)	AAC0--48h (% h)	AAC0--48h/dose; (% h kg µg^−1)	Pharmacological activity relative to iv route (%)
iv solution of sCT	5	211.05±63.03	42.21±12.61	—
Pulmonary sCT solution	25	302.08±100.93	12.08±4.04^¥	28.63±9.56
Pulmonary blank nanoparticles	25	25.10±5.56	1.00±0.22	2.4±0.53
Pulmonary sCT nanoparticles	25	1259.95±147.19	50.40±5.89^∗¥	119.4±13.95

∗Significant difference (𝑃<0.001) between iv solution of sCT and pulmonary sCT nanoparticles, ^¥significant difference (𝑃<0.001) between pulmonary sCT solution and pulmonary sCT nanoparticles.